**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

A 5-month-old female infant developed severe combined immmune dysfunction following treatment with vincristine, cyclophosphamide, daunorubicin, asparaginase, cytarabine \[Ara-C\], methylprednisolone, lestaurtinib, etoposide, methotrexate and hydrocortisone for acute lymphoblastic leukaemia (ALL) \[*dosages and durations of treatments to reactions onsets not stated; not all routes stated*\].

The infant, who was born with acute lymphoblastic leukaemia, started receiving treatment with vincristine, cyclophosphamide, daunorubicin, asparaginase, cytarabine, methylprednisolone, lestaurtinib, etoposide and granulocyte colony-stimulating factor \[*specific drug not stated*\]. Additionally, she started receiving triple intrathecal therapy with cytarabine, methotrexate and hydrocortisone. She achieved complete remission at the age of 1.5 months. At the age of six months, she started receiving IV methotrexate. At the age of 17 months, she developed a rash that occurred monthly. The rash improved with immunoglobulin therapy over the next two months. At the age of 21 months, after receiving a dose of IV methotrexate, the rash worsened significantly, and she also developed erythroderma of her extremities, scalp and face with overlying thick yellow hyperkeratosis mostly covering her trunk.

Antineoplastics were discontinued at the age of 22 months. At the age of 23 months, the infant was hospitalised for worsening skin rash, diarrhoea, vomiting and feeding intolerance. Subsequently, she was transferred to the tertiary care centre. During a hospital course since the birth, she developed multiple infections including *Klebsiella* septic shock at the age of five months, and methicillin-sensitive *Staphylococcus aureus* sepsis and *Clostridium difficile* colitis owing to failure of prolonged vancomycin therapy. She received fecal transplant twice from a parent at the age of 17 months and 22 months. Additionally, she developed *staphylococcus epidermis* conjunctivitis at the age of 21 months and central line associated blood-stream infection with *Enterococcus fecalis*, *Staphylococcus epidermis*, Klebsiella species and *Candida parapsilosis* at the age of 23 months. Furthermore, she developed otitis externa and viral (coronavirus) bronchiolitis at the age of 24 months. Other complications included pulmonary oedema, hypertension, persistent vomiting, diarrhoea and neutropenic fevers. At the age of 22 months, a punch biopsy of rash revealed subacute cytotoxic dermatitis along with features of erythema multiforme and confluent upper dermal necrosis. At the age of 23 months, she was found to have hypogammaglobulinaemia and lymphopenia. Laboratory investigations at the age of 23 months revealed WBC count of 4.3 x 10^3^/µL, absolute lymphocyte count of 0.12 x 10^3^/µL, absolute neutrophil count of 3.65 x 10^3^/µL and immunoglobulin G level of 208 mg/dL. At the age of 25 months, oesophagogastroduodenoscopy and colonoscopy revealed graft-versus-host disease-like findings. Laboratory investigations at the age of 25 months revealed WBC count of 5.4 x 10^3^/µL, absolute lymphocyte count of 0.5 x 10^3^/µL, absolute neutrophil count of 4.2 x 10^3^/µL, immunoglobulin G level of 1290 mg/dL, CD3+ T cells of 39 /mm^3^, CD4+ T cells of 37 /mm^3^, CD8+ T cells of 2 /mm^3^, CD19+ B cells of 23 /mm^3^, CD16+CD56+ NK cells of 519 /mm^3^, CD4+/45RA+ T cells of 24 /mm^3^. A mitogen assay revealed a reading of \<5%. Whole exome sequencing did not show any primary immunodeficiencies. Severe combined immune dysfunction was diagnosed, and she started receiving treatment with corticosteroids, immunoglobulin and sirolimus. Two to three days later, clinical improvement was noted. Additionally, she was started on fungal and *Pneumocystis jirovecii* pneumonia prophylaxis. She was isolated and closely monitored for infections. She continued to show improvement in diarrhoea, vomiting and rash. At the age of 28 months, she had CD19+CD27+IgM− B cells of 6 /mm^3^. At the age of 28 months, antigen assay showed absence of antigen. At the age of 32 months, antigen assay showed decreased level of antigen. At the age of 34 months, laboratory investigations revealed improvement in the absolute lymphocyte count to 2.32 x 10^3^/µL, WBC count of 2.32 x 10^3^/µL, absolute neutrophil count of 5.47 x 10^3^/µL, immunoglobulin G level of 553 mg/dL, CD3 + T cells of 553 /mm^3^, CD4+ T cells of 1650 /mm^3^, CD8+ T cells of 488 /mm^3^, CD19 + B cells of 441 /mm^3^, CD16+CD56+ NK cells of 186 /mm^3^, CD4+/45RA+ T cells of 926 /mm^3^. Results of mitogen assay were normal. Subsequently, her immunodeficiency symptoms resolved. At the age of 4 years, she was doing well.

**Author comment:** *\"We present a case of transient severe immunodeficiency secondary to therapy for infantile ALL with remission over time.\" \"This case demonstrates that \[acute lymphoblastic leukaemia\] and its therapy can be associated with complications of severe combined immune dysfunction.\"*
